Enanta Pharmaceuticals Releases PEARL-III Study Results
Enanta Pharmaceuticals Releases PEARL-III Study Results
About this item
Full title
Enanta Pharmaceuticals Releases PEARL-III Study Results
Publisher
Jacksonville: Close-Up Media, Inc
Journal title
Entertainment Close - Up, 2014
Language
English
Formats
Publication information
Publisher
Jacksonville: Close-Up Media, Inc
Subjects
More information
Scope and Contents
Contents
According to a release, PEARL-III is one of the six phase 3 registrational studies conducted by AbbVie for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection using a regimen containing Enanta's lead protease inhibitor ABT-450.
Alternative Titles
Full title
Enanta Pharmaceuticals Releases PEARL-III Study Results
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1504287713
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1504287713
How to access this item
Log in as a Library member
